1.            Meirovitz, A., Gross, M., Cohen, S., Popovtzer, A. & Barak, V. Effect of irradiation on cytokine production in cancer patients. Int. J. Biol. Markers 37, 360–367 (2022).

2.            Meirovitz, A., Baider, L., Peretz, T., Stephanos, S. & Barak, V. PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics. Anticancer Res. 42, 5487–5496 (2022).

3.            Barak, V., Kalickman, I. & Pe’Er, J. SIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma. Anticancer Res. 42, 1447–1453 (2022).

4.            Meirovitz, A., Baider, L., Peretz, T., Stephanos, S. & Barak, V. Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). Tumor Biol. 43, 341–349 (2021).

5.            Meirovitz, A. et al. Clinical applicability of the proliferation marker thymidine kinase 1 in head and neck cancer patients. Anticancer Res. 41, 1083–1087 (2021).

6.            Barak, V., Itzkovich, D., Einarsson, R., Gofrit, O. & Pode, D. Non-invasive detection of bladder cancer by UBC rapid test, ultrasonography and cytology. Anticancer Res. 40, 3967–3972 (2020).

7.            Nicolini, A. et al. The use of immunotherapy to treat metastatic breast cancer. Curr. Med. Chem. 26, 941–962 (2019).

8.            Filippou, P. S. et al. Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clin. Chem. Lab. Med. 56, 1945–1953 (2018).

9.            Dahan, S. et al. The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia. Psychiatry Res. 268, 467–472 (2018).

10.          Nicolini, A. et al. An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag. Res. 10, 6879–6886 (2018).

11.          Duffy, M. J. et al. Validation of new cancer biomarkers: The official position of the European Group on Tumor Markers . Biochim. Clin. 41, 102–113 (2017).

12.          Gross, M. et al. The diagnostic and prognostic value of sIL-2R as an immune biomarker in head and neck cancers. Anticancer Res. 36, 4347–4352 (2016).

13.          Barak, V. et al. Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. Anticancer Res. 35, 6755–6760 (2015).

14.          Barak, V. et al. The diagnostic and prognostic value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients. Anticancer Res. 35, 5519–5524 (2015).

15.          Barak, V., Pe’er, J., Kalickman, I. & Frenkel, S. Erratum: VEGF as a Biomarker for Metastatic Uveal Melanoma in Humans (Current Eye Research (2011) 36 (386-390)). Curr. Eye Res. 40, 862 (2015).

16.          Landesberg, G. et al. Myocardial dysfunction in severe sepsis and septic shock: No correlation with inflammatory cytokines in real-life clinical setting. Chest 148, 93–102 (2015).

17.          Duffy, M. J. et al. Validation of new cancer biomarkers: A position statement from the european group on tumor markers. Clin. Chem. 61, 809–820 (2015).

18.          Gatt, M. E. et al. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation. Anticancer Res. 35, 3019–3026 (2015).

19.          Karlikova, M., Topolcan, O., Wolfe, O. T. J., Barak, V. & Zima, T. Optimal Use of Biomarkers in Oncology. Biomed Res. Int. 2015, (2015).

20.          Czerninski, R., Basile, J. R., Kartin-Gabay, T., Laviv, A. & Barak, V. Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: A pilot study. Oral Dis. 20, 477–481 (2014).

21.          Arnson, Y. et al. Vitamin D inflammatory cytokines and coronary events: A comprehensive review. Clin. Rev. Allergy Immunol. 45, 236–247 (2013).

22.          Frenkel, S., Zloto, O., Pe’er, J. & Barak, V. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. Investig. Ophthalmol. Vis. Sci. 54, 490–493 (2013).

23.          Sölétormos, G. et al. Design of tumor biomarker-monitoring trials: A proposal by the European Group on Tumor Markers. Clin. Chem. 59, 52–59 (2013).

24.          Elbaz, M. et al. Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy 2J/dy 2J mouse. Ann. Neurol. 71, 699–708 (2012).

25.          Sivan, S. et al. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin. Dev. Immunol. 2012, (2012).

26.          Oberbaum, M. et al. Effect of traumeel S on cytokine profile in a cecal ligation and puncture (CLP) sepsis model in rats. J. Altern. Complement. Med. 17, 909–913 (2011).

27.          Barak, V., Pe’er, J., Kalickman, I. & Frenkel, S. VEGF as a biomarker for metastatic uveal melanoma in humans. Curr. Eye Res. 36, 386–390 (2011).

28.          Beloosesky, Y., Weiss, A., Hershkovitz, A., Hendel, D. & Barak, V. Serum transforming growth factor beta-1 post hip fracture repair in elderly patients. Cytokine 54, 56–60 (2011).

29.          Nicolini, A. et al. Additional 5-FU-LV significantly increases survival in gastrointestinal cancer. Front. Biosci. - Elit. 3 E, 1475–1482 (2011).

30.          Hendler, K. et al. Trends in liver function tests: A comparison with serum tumor markers in metastatic uveal melanoma (Part 2). Anticancer Res. 31, 351–357 (2011).

31.          Barak, V. et al. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (Part 1). Anticancer Res. 31, 345–349 (2011).

32.          Agmon-Levin, N. et al. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann. Rheum. Dis. 70, 145–150 (2011).

33.          Arad, I., Bar-Oz, B., Ergaz, Z., Nir, A. & Barak, V. Interleukin-6 and n-terminal pro-brain natriuretic peptide cord blood levels in premature infants: Correlations with perinatal variables. Isr. Med. Assoc. J. 12, 419–423 (2010).

34.          Amital, H. et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: Is it time to routinely supplement patients with SLE with vitamin D? Ann. Rheum. Dis. 69, 1155–1157 (2010).

35.          Dror, R. et al. Characterizing the involvement of the nuclear factorkappa b (NFκB) transcription factor in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 51, 1811–1816 (2010).

36.          Meirovitz, A. et al. Cytokines levels, Severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer - a prospective pilot study. Radiat. Oncol. 5, (2010).

37.          Vaisman, N., Press, J., Leibovitz, E., Boehm, G. & Barak, V. Short-term effect of prebiotics administration on stool characteristics and serum cytokines dynamics in very young children with acute diarrhea. Nutrients 2, 683–692 (2010).

38.          Goldschmidt, N., Verber, A., Neuman, T., Kalikhman, I. & Barak, V. Vascular endothelial growth factors (VEGF) as a major parameter for diagnosis and follow up of a patient with POEMS syndrome . J. Neurol. Sci. 27, 348–352 (2010).

39.          Barak, V., Holdenrieder, S., Nisman, B. & Stieber, P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomarkers 6, 191–196 (2009).

40.          Nisman, B. et al. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res. 29, 4827–4832 (2009).

41.          Barak, V. et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J. Autoimmun. 33, 178–182 (2009).

42.          Nisman, B. et al. The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: A pilot study. Anticancer Res. 29, 4281–4285 (2009).

43.          Waknine-Grinberg, J. H., El-On, J., Barak, V., Barenholz, Y. & Golenser, J. The immunomodulatory effect of Sambucol on leishmanial and malarial infections. Planta Med. 75, 581–586 (2009).

44.          Mashiah, J., Brenner, S., Pessach, Y., Barak, V. & Schachter, J. Differences in cytokine levels in melanoma patients with and without redness (Brenner sign). Anticancer Res. 29, 1793–1796 (2009).

45.          Gutman, G. et al. Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity. Fertil. Steril. 91, 1837–1841 (2009).

46.          Rott, D. et al. The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction. Cardiology 112, 56–59 (2008).

47.          Gutman, G. et al. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis. Fertil. Steril. 89, 922–926 (2008).

48.          Nisman, B. et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: Association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br. J. Cancer 98, 77–79 (2008).

49.          Molina, R. et al. Tumor markers in breast cancer - European Group on Tumor Markers (EGTM) recommendations. Intern. Med. Clin. Lab. 15–16, 29–31 (2007).

50.          Barak, V. et al. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker. Investig. Ophthalmol. Vis. Sci. 48, 4399–4402 (2007).

51.          Portugal, M., Barak, V., Ginsburg, I. & Kohen, R. Interplay among oxidants, antioxidants, and cytokines in skin disorders: Present status and future considerations. Biomed. Pharmacother. 61, 412–422 (2007).

52.          Folberg, R. et al. Modeling the behavior of uveal melanoma in the liver. Investig. Ophthalmol. Vis. Sci. 48, 2967–2974 (2007).

53.          Barak, V. et al. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 27, 1897–1900 (2007).

54.          Handzel, Z. T. et al. Increased Th1 and Th2 type cytokine production in patients with active tuberculosis. Isr. Med. Assoc. J. 9, 479–483 (2007).

55.          Amital, H., Barak, V., Winkler, R. E. & Rubinow, A. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Annals of the New York Academy of Sciences vol. 1110 649–660 (2007).

56.          Orbach, H. et al. Novel biomarkers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Annals of the New York Academy of Sciences vol. 1109 385–400 (2007).

57.          Beloosesky, Y. et al. Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. Journals Gerontol. - Ser. A Biol. Sci. Med. Sci. 62, 420–426 (2007).

58.          Kadkol, S. S. et al. Osteopontin expression and serum levels in metastatic uveal melanoma: A pilot study. Investig. Ophthalmol. Vis. Sci. 47, 802–806 (2006).

59.          Nisman, B., Heching, N., Biran, H., Barak, V. & Peretz, T. The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumor Biol. 27, 8–16 (2006).

60.          Vaisman, N., Zaruk, Y., Shirazi, I., Kaysar, N. & Barak, V. The effect of fish oil supplementation on cytokine production in children. Eur. Cytokine Netw. 16, 194–198 (2005).

61.          Reichert, F. et al. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies. Eur. J. Haematol. 75, 41–46 (2005).

62.          Molina, R. et al. Tumor markers in breast cancer - European group on tumor markers recommendations. Tumor Biol. 26, 281–293 (2005).

63.          Raveh, D., Shemesh, O., Ashkenazi, Y. J., Winkler, R. & Barak, V. Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome. Pediatr. Nephrol. 19, 1281–1284 (2004).

64.          Barak, V. et al. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil. Steril. 82, 415–420 (2004).

65.          Barak, V., Kalickman, I., Halperin, T., Birkenfeld, S. & Ginsburg, I. PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production. Eur. Cytokine Netw. 15, 203–209 (2004).

66.          Barak, V., Goike, H., Panaretakis, K. W. & Einarsson, R. Clinical utility of cytokeratins as tumor markers. Clin. Biochem. 37, 529–540 (2004).

67.          Vaisman, N. et al. Changes in cytokine production and impaired hematopoiesis in patients with anorexia nervosa: The effect of refeeding. Cytokine 26, 255–261 (2004).

68.          Abramov, Y. et al. Markedly elevated levels of inflammatory cytokines in maternal serum and peritoneal washing during arrested labor. Acta Obstet. Gynecol. Scand. 83, 358–363 (2004).

69.          Shapira, J. et al. Cytokine levels in gingival crevicular fluid of erupting primary teeth correlated with systemic disturbances accompanying teething. Pediatr. Dent. 25, 441–448 (2003).

70.          Vaisman, N., Leibovitz, E., Dagan, R. & Barak, V. The involvement of IL-6 and IL-8 in acute invasive gastroenteritis of children. Cytokine 22, 194–197 (2003).

71.          Nisman, B. et al. Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Res. 23, 1939–1942 (2003).

72.          Zahalka, M. A., Barak, V., Traub, L. & Moroz, C. PLIF induces IL-10 production in monocytes: a calmodulin-p38 mitogen-activated protein kinase-dependent pathway. FASEB J. 17, 955–957 (2003).

73.          Scheinowitz, M. et al. Dalteparin sodium (Fragmin®). Administration following acute infarction does not affect myocardial perfusion and function in swine. Cardiovasc. Drugs Ther. 16, 303–309 (2002).

74.          Barak, V., Birkenfeld, S., Halperin, T. & Kalickman, I. The effect of herbal remedies on the production of human inflammatory and anti-inflammatory cytokines. Isr. Med. Assoc. J. 4, 919–922 (2002).

75.          Nisman, B. et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94, 2914–2922 (2002).

76.          Abramov, Y., Anteby, S. O., Fasouliotis, S. J. & Barak, V. The role of inflammatory cytokines in Meigs’ syndrome. Obstet. Gynecol. 99, 917–919 (2002).

77.          Gavish, Z. et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51, 73–83 (2002).

78.          Barak, V., Nisman, B., Hubert, A., Lyass, O. & Peretz, T. Cytokeratins - Clinical utility in breast cancer. J. Clin. Ligand Assay 25, 40–42 (2002).

79.          Abrahamov, D. et al. Plasma vascular endothelial growth factor level is a predictor of the severity of postoperative capillary leak syndrome in neonates undergoing cardiopulmonary bypass. Pediatr. Surg. Int. 18, 54–59 (2002).

80.          Weiss, L. et al. Cytokine production in linomide-treated NOD mice and the potential role of a Th1/Th2 shift on autoimmune and anti-inflammatory processes. Cytokine 19, 85–93 (2002).

81.          Zecchina, G. et al. Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J. Hematotherapy Stem Cell Res. 10, 769–776 (2001).

82.          Abramov, Y. et al. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndome. Fertil. Steril. 76, 51–57 (2001).

83.          Barak, V., Halperin, T. & Kalickman, I. The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines. Eur. Cytokine Netw. 12, 290–296 (2001).

84.          Ben-Ishay, Z. & Barak, V. Bone marrow stromal dysfunction in mice administered cytosine arabinoside. Eur. J. Haematol. 66, 230–237 (2001).

85.          Condiotti, R., Zakai, Y. B., Barak, V. & Nagler, A. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Exp. Hematol. 29, 104–113 (2001).

86.          Abramov, Y., Anteby, S. O., Fasouliotis, S. J. & Barak, V. Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. Am. J. Obstet. Gynecol. 184, 354–355 (2001).

87.          Abramov, Y., Anteby, S. O., Fatum, M., Fasouliotis, S. J. & Barak, V. The kinetics of leptin in Meigs’ syndrome. Gynecol. Oncol. 83, 316–318 (2001).

88.          Barak, V. et al. Prognostic efficacy of TPS in breast cancer. J. Tumor Marker Oncol. 15, 171–176 (2000).

89.          Nisman, B., Heching, N. & Barak, V. Serum tumor markers in resectable and nonresectable non-small cell lung cancer. J. Tumor Marker Oncol. 15, 195–206 (2000).

90.          Nagler, R. M., Barak, V. & Nagler, A. Short term systemic effects of head and neck irradiation. Anticancer Res. 20, 1865–1870 (2000).

91.          Abramov, D. et al. Increased levels of basic fibroblast growth factor are found in the cross-clamped heart during cardiopulmonary bypass. Can. J. Cardiol. 16, 313–318 (2000).

92.          Kori, M. et al. Specific in vitro proliferative immune responses and lymphokine production in Ethiopian children with and without tuberculosis. Infection 28, 42–45 (2000).

93.          Houri-Haddad, Y., Soskolne, W. A., Halabi, A., Barak, V. & Shapira, L. Repeat bacterial challenge in a subcutaneous chamber model results in augmented tumour necrosis factor-α and interferon-γ response, and suppression of interleukin-10. Immunology 99, 215–220 (2000).

94.          Israel, Z. H., Lossos, A., Barak, V., Soffer, D. & Siegal, T. Multifocal demyelinative leukoencephalopathy associated with 5- fluorouracil and levamisole. Acta Oncol. (Madr). 39, 117–120 (2000).

95.          Aizman, I. et al. Neoplastic cell activation and proliferative response to CD40-ligand characterize recurrent leukemic bouts in an unusual case of low grade lymphoma. Leuk. Lymphoma 36, 613–623 (2000).

96.          Pizov, R. et al. High oxygen concentration exacerbates cardiopulmonary bypass-induced lung injury. J. Cardiothorac. Vasc. Anesth. 14, 519–523 (2000).

97.          Einarsson, R. & Barak, V. TPS(TM): A cytokeratin serum tumor marker for effective of cancer patients with focus on breast cancer. J. Clin. Ligand Assay 22, 348–351 (1999).

98.          Nisman, B. et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res. 19, 3549–3552 (1999).

99.          Levine, J. et al. Low CSF soluble interleukin 2 receptor levels in acute depression. J. Neural Transm. 106, 1011–1015 (1999).

100.        Levine, J. et al. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40, 171–176 (1999).

101.        Tomer, Y., Barak, V., Gilburd, B. & Shoenfeld, Y. Cytokines in experimental autoimmune vasculitis: Evidence for a Th2 type response. Clin. Exp. Rheumatol. 17, 521–526 (1999).

102.        Barak, V. et al. Cytokines in Gaucher’s disease. Eur. Cytokine Netw. 10, 205–210 (1999).

103.        Krause, I. et al. Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin. Exp. Immunol. 117, 190–197 (1999).

104.        Blank, M. et al. Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. Arthritis Rheum. 42, 1421–1432 (1999).

105.        Voronov, E. et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1α expression. Cancer Res. 59, 1029–1035 (1999).

106.        Geva, E. et al. Follicular fluid levels of vascular endothelial growth factor: Are they predictive markers for ovarian hyperstimulation syndrome? J. Reprod. Med. Obstet. Gynecol. 44, 91–96 (1999).

107.        Hirshberg, B. et al. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma. Am. J. Hematol. 60, 143–147 (1999).

108.        Rosen, G. et al. Activation of murine macrophages by lipoprotein and lipooligosaccharide of Treponema denticola. Infect. Immun. 67, 1180–1186 (1999).

109.        Barak, V., Nisman, B. & Polliack, A. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur. J. Haematol. 62, 71–75 (1999).

110.        Nisman, B., Lafair, J., Lyass, O., Dranitzki-Elhalel, M. & Barak, V. Serum Levels of CEA, SCC, TPS and CYFRA 21-1 in Hemodialysis Patients. J. Tumor Marker Oncol. 13, 87–93 (1998).

111.        Nisman, B., Lafair, J., Lyass, O., Dranitzki-Elhalel, M. & Barak, V. Serum Levels of CEA, SCC, TPS and CYFRA 21-1 in Hemodialysis Patients. J. Tumor Marker Oncol. 13, 33–39 (1998).

112.        Blank, M. et al. Oral tolerance to low dose β2-glycoprotein I: Immunomodulation of experimental antiphospholipid syndrome. J. Immunol. 161, 5303–5312 (1998).

113.        Amital, H. et al. Immunomodulation of murine experimental SLE-like disease by interferon-γ. Lupus 7, 445–454 (1998).

114.        Barak, V. et al. Prevalence of hypophosphatemia in sepsis and infection: The role of cytokines. Am. J. Med. 104, 40–47 (1998).

115.        Nisman, B. et al. Cytokeratin markers in malignant pleural mesothelioma. Cancer Detect. Prev. 22, 416–421 (1998).

116.        Nagler, A., Bishara, A., Brautbar, C. & Barak, V. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Cytokines, Cell. Mol. Ther. 4, 161–167 (1998).

117.        Barak, V., Nisman, B., Polliack, A., Vannier, E. & Dinarello, C. A. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur. Cytokine Netw. 9, 33–39 (1998).

118.        Bishara, A. et al. Cytokine production in human mixed leukocyte reactions performed in serum-free media. J. Immunol. Methods 215, 187–190 (1998).

119.        Nisman, B. et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: Does the combined use of cytokeratin markers give any additional information? Cancer 82, 1850–1859 (1998).

120.        Blank, M. et al. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony- stimulating factor expression. Arthritis Rheum. 41, 224–232 (1998).

121.        Deutsch, E., Nisman, B., Kaufman, M. & Barak, V. Cytokine evaluation in throat infections. Ann. Otol. Rhinol. Laryngol. 107, 713–716 (1998).

122.        Barak, V. et al. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 10, 977–983 (1998).

123.        Shapira, L., Barak, V., Soskolne, W. A., Halabi, A. & Stabholz, A. Effects of tetracyclines on the pathologic activity of endotoxin: in vitro and in vivo studies. Adv. Dent. Res. 12, 119–122 (1998).

124.        Van Dalen, A. et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int. J. Biol. Markers 13, 10–15 (1998).

125.        Shapira, L., Soskolne, A., Halabi, A., Barak, V. & Stabholz, A. Induction of tumor necrosis factor α and interleukin-1β in subcutaneously implanted chamber by lipopolysaccharide. Innate Immun. 4, 325–329 (1997).

126.        Barak, V. et al. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J. Tumor Marker Oncol. 12, 17–25 (1997).

127.        Toren, A., Barak, V., Novick, D. & Nagler, A. Soluble interferon-γ receptor and interferon-γ in patients undergoing allogeneic bone marrow transplantation for hematological malignancies. Cytokines, Cell. Mol. Ther. 3, 153–158 (1997).

128.        Hasdai, D. et al. Serum basic fibroblast growth factor levels in patients with ischemic heart disease. Int. J. Cardiol. 59, 133–138 (1997).

129.        Levi-Schaffer, F., Segal, V., Barak, V., Rubinchik, E. & Nagler, A. Regulation of the functional activity of mast cells and fibroblasts by mononuclear cells in murine and human chronic graft-vs.-host disease. Exp. Hematol. 25, 238–245 (1997).

130.        Shapira, L., Soskolne, A., Halabi, A., Barak, V. & Stabholz, A. Induction of tumor necrosis factor α and interleukin-1β in subcutaneously implanted chamber by lipopolysaccharide. J. Endotoxin Res. 4, 325–329 (1997).

131.        Abramov, Y., Barak, V., Nisman, B. & Schenker, J. G. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil. Steril. 67, 261–265 (1997).

132.        Levy, Y., George, J., Barak, V. & Shoenfeld, Y. Early detection of recurrent mono-metastases of breast cancer to endocrine tissues by following CEA levels. Oncol. Rep. 4, 623–624 (1997).

133.        BenEzra, D., Maftzir, G. & Barak, V. Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behcet disease. Am. J. Ophthalmol. 123, 593–598 (1997).

134.        Gilad, R., Lampl, Y., Eshel, Y., Barak, V. & Sarova-Pinhas, I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br. J. Rheumatol. 36, 190–193 (1997).

135.        Peretz, T. et al. Combination of interferon and tamoxifen for patients with advanced breast cancer and negative oestrogen receptors. Breast 6, 190–193 (1997).

136.        Merimsky, O. et al. Elevated breast cancer serum markers in otherwise healthy women. Oncol. Rep. 4, 829–832 (1997).

137.        Shapira, L. et al. Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide-induced lesions in vivo and TNfα processing in vitro. J. Periodontal Res. 32, 183–188 (1997).

138.        Zandman-Goddard, G. et al. The effects of early and late administration of M-20 derived interleukin-1 inhibitor on experimental systemic lupus erythematosus. Immunol. Lett. 53, 77–82 (1996).

139.        Shimonovitz, S. et al. Cytokine-mediated regulation of type IV collagenase expression and production in human trophoblast cells. J. Clin. Endocrinol. Metab. 81, 3091–3096 (1996).

140.        Levi-Schaffer, F. et al. Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 87, 155–161 (1996).

141.        Isaac, R. et al. Breast cancer: Screening, detection, tumor markers and surgical management. J. Tumor Marker Oncol. 11, 131–155 (1996).

142.        Van Dalen, A. et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. Breast 5, 82–88 (1996).

143.        Shapira, L. et al. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: Correlation with inhibition of cytokine secretion. Infect. Immun. 64, 825–828 (1996).

144.        Nagler, A., Shur, I., Barak, V. & Fabian, I. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation. Leuk. Res. 20, 637–643 (1996).

145.        Yakovlev, E., Kalichman, I., Pisanti, S., Shoshan, S. & Barak, V. Levels of cytokines and collagen type I and type III as a function of age in human gingivitis. J. Periodontol. 67, 788–793 (1996).

146.        Shapira, L. et al. Human monocyte response to cementum extracts from periodontally diseased teeth: Effect of conditioning with tetracycline. J. Periodontol. 67, 682–687 (1996).

147.        Condiotti, R., Slavin, S., Barak, V. & Nagler, A. The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. Leuk. Res. 20, 57–63 (1996).

148.        Revel, A. et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil. Steril. 66, 66–71 (1996).

149.        Vaisman, N. et al. Defective in vitro granulopoiesis in patients with anorexia nervosa. Pediatr. Res. 40, 108–111 (1996).

150.        Abramov, Y. et al. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum. Reprod. 11, 1381–1386 (1996).

151.        Deutsch, V. R. et al. Stem cell factor (SCF) synergizes with megakaryocyte colony stimulating activity in post-irradiated aplastic plasma in stimulating human megakaryocytopoiesis. Med. Oncol. 13, 31–42 (1996).

152.        Hasdai, D. et al. Increased serum concentrations of interleukin-1β in patients with coronary artery disease. Heart 76, 24–28 (1996).

153.        Nagler, A. et al. Elevated inflammatory cytokine levels in bone marrow graft rejection. Transplantation 60, 943–948 (1995).

154.        Barak, V., Roisman, I. & Kaufman, B. Utility of Ca 19-9 tumor marker in pancreatic carcinoma. Harefuah 129, 217–219 (1995).

155.        Geva, E. et al. Secondary amenorrhoea due to persistent corpus luteum in brucellosis. Lancet 345, 201 (1995).

156.        Leibovici, L. et al. Imbalance of immune responses in patients with chronic and widespread fungal skin infection. Clin. Exp. Dermatol. 20, 390–394 (1995).

157.        Barak, V. Soluble cytokine receptors in disease. Isr. J. Med. Sci. 31, 565–571 (1995).

158.        Abramov, Y. et al. Postpartum systemic capillary leak syndrome: a possible etiology. Acta Obstet. Gynecol. Scand. 74, 395–398 (1995).

159.        Pode, D. et al. Screening for prostate cancer. Isr. J. Med. Sci. 31, 125–128 (1995).

160.        Barak, V. Cytokines and soluble cytokine receptors in Behcet’s disease. Isr. J. Med. Sci. 31, 374–375 (1995).

161.        Wieder, R., Barak, V. & Ben-Ishay, Z. High-efficiency retroviral gene transfer into murine high-proliferative-potential cells cycle-activated by cytosine arabinoside. Hum. Gene Ther. 6, 865–871 (1995).

162.        Barak, V., Schaffer, F. L., Nisman, B. & Nagler, A. Cytokine dysregulation in chronic graft versus host disease. Leuk. Lymphoma 17, 169–173 (1995).

163.        Edelmann, D. Z., Peretz, T., Barak, V. & Anteby, S. O. Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer 5, 443–448 (1995).

164.        Barak, V., Nisman, B., Roisman, I., Barak, Y. & Levine, J. Changes in interleukin-1 β and soluble interleukin-2 receptor levels in csf and serum of schizophrenic patients. J. Basic Clin. Physiol. Pharmacol. 6, 61–70 (1995).

165.        Dann, E. J. et al. Hairy cell leukemia: Results of 2-chlorodeoxyadenosine therapy in Jerusalem. Leuk. Lymphoma 14, 127–131 (1994).

166.        Shapira, L. et al. Sequential manifestation of different forms of early-onset periodontitis. A case report. J. Periodontol. 65, 631–635 (1994).

167.        Shapira, L., Soskolne, W. A., Sela, M. N., Offenbacher, S. & Barak, V. The secretion of PGE2, IL-1 beta, IL-6, and TNF alpha by adherent mononuclear cells from early onset periodontitis patients. J. Periodontol. 65, 139–146 (1994).

168.        Manetti, R. et al. Interleukin-1 favours the in vitro development of type 2 T helper (Th2) human T-cell clones. Res. Immunol. 145, 93–100 (1994).

169.        Shimonovitz, S. et al. High concentration of soluble interleukin-2 receptors in ejaculate with low sperm motility. Hum. Reprod. 9, 653–655 (1994).

170.        Hahn, T. et al. Differential responses of fetal, neonatal, and adult myelopoietic progenitors to interferon and tumor necrosis factor. Exp. Hematol. 22, 114–121 (1994).

171.        Engelhard, D., Singer, R., Nagler, A. & Barak, V. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after t-lymphocyte depleted bone marrow transplantation for hematological neoplasias. Leuk. Lymphoma 12, 273–280 (1994).

172.        Nagler, A., Ackerstein, A., Barak, V. & Slavin, S. Treatment of Chronic Myelogenous Leukemia with Recombinant Human Interleukin-2 and Interferon-α2a. J. Hematother. 3, 75–82 (1994).

173.        Barak, V. & Ben-Ishay, Z. Cytokine and growth factor gene expression by bone marrow stroma of mice with damaged hematopoiesis and during regeneration. Leuk. Res. 18, 733–739 (1994).

174.        Barak, V. et al. Serum interleukin 1β levels as a marker in hairy cell leukemia: Correlation with disease status and sIL-2R levels. Leuk. Lymphoma 14, 33–39 (1994).

175.        Fibach, E., Rigel, M., Peled, T., Treves, A. J. & Barak, V. The effect of human myelomonocytic leukemic cell line (m20) derived IL-1 inhibitor on human erythroid cell development. Leuk. Lymphoma 15, 327–332 (1994).

176.        Barak, V., Peritt, D., Yanai, P., Halperin, T. & Treves, A. J. In vivo anti inflammatory effects of the M20 IL-1 Inhibitor: I. Effects on acute inflammatory parameters. Biotherapy 6, 263–270 (1993).

177.        Barak, V. et al. In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants. Biotherapy 6, 271–277 (1993).

178.        Shapira, L. et al. Rapid fluorometric quantificaition of monocyte attachment in tissue culture wells. J. Immunol. Methods 165, 93–98 (1993).

179.        BenEzra, D., Maftzir, G., Kalichman, I. & Barak, V. Serum levels of interleukin-2 receptor in ocular Behcet’s disease. Am. J. Ophthalmol. 115, 26–30 (1993).

180.        Putterman, C., Barak, V., Caraco, Y., Neuman, T. & Shalit, M. Episodic angioedema with eosinophilia: A case associated with T cell activation and cytokine production. Ann. Allergy 70, 243–248 (1993).

181.        Barak, V. et al. The M20 IL-1 inhibitor prevents onset of adjuvant arthritis. Biotherapy 4, 317–323 (1992).

182.        Peritt, D. et al. The M20 IL-1 inhibitor. II. Biological characterization. J. Immunol. Methods 155, 167–174 (1992).

183.        Peritt, D. et al. The M20 IL-1 inhibitor. I. Purification by preparative isoelectric focusing in free solution. J. Immunol. Methods 155, 159–165 (1992).

184.        Peled, T. et al. Effect of M20 interleukin-1 inhibitor on normal and leukemic human myeloid progenitors. Blood 79, 1172–1177 (1992).

185.        Gofrit, O. et al. Prostatic specific antigen for detection and monitoring of prostatic cancer. Harefuah 122, 345-348,408 (1992).

186.        Barak, V. et al. The correlation between interleukin 2 and soluble interleukin 2 receptors to oestradiol, progesterone and testosterone levels in periovulatory follicles of in-vitro fertilization patients. Hum. Reprod. 7, 926–929 (1992).

187.        Barak, V. et al. Interleukin-1: Local production and modulation of human granulosa luteal cells steroidogenesis. Fertil. Steril. 58, 719–725 (1992).

188.        Rotshenker, S., Aamar, S. & Barak, V. Interleukin-1 activity in lesioned peripheral nerve. J. Neuroimmunol. 39, 75–80 (1992).

189.        Barak, V., Kalickman, I., Polliack, A. & Ginzburg, M. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-hodgkin’s lymphoma and chronic lymphocytic leukemia. Leuk. Lymphoma 7, 431–438 (1992).

190.        Isacson, R. et al. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with decarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. Immunol. Lett. 33, 127–134 (1992).

191.        Kalinkovich, A. et al. Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin. Exp. Immunol. 89, 351–355 (1992).

192.        Roisman, I. et al. Breast malignancies in adolescents in Israel (1967-1989). Breast Dis. 5, 149–168 (1992).

193.        Barak, V. et al. The correlation of interleukin 1 and tumour necrosis factor to oestradiol, progesterone and testosterone levels in periovulatory follicular fluid of in-vitro fertilization patients. Hum. Reprod. 7, 462–464 (1992).

194.        Mordel, N. et al. CA-125 is present in significant concentrations in periovulatory follicles of in vitro fertilization patients. Fertil. Steril. 57, 377–380 (1992).

195.        Barak, V. et al. The specific IL-1 inhibitor from the human M20 cell line is distinct from the IL-1 receptor antagonist. Lymphokine Cytokine Res. 10, 437–442 (1991).

196.        Roisman, I. et al. Breast developmental disorders and masses in childhood and adolescence. Harefuah 121, 463–468 (1991).

197.        Roisman, I., Barak, V., Okon, E., Manny, J. & Durst, A. L. Benign cystosarcoma phyllodes of breast in an adolescent female. Breast Dis. 4, 299–305 (1991).

198.        Friedman, G. et al. Recombinant human interleukin-1 suppresses lipoprotein lipase activity, but not expression of lipoprotein lipase mRNA in mesenchymal rat heart cell cultures. BBA - Gene Struct. Expr. 1089, 83–87 (1991).

199.        Roisman, I. et al. Adenolipoma of breast. Breast Dis. 4, 153–159 (1991).

200.        Roisman, I., Gimmon, Z., Barak, V. & Durst, A. L. Appropriate diagnostic steps for proper clinical evaluation of breast lesions in the community. Harefuah 120, 266–270 (1991).

201.        Roisman, I., Gimon, Z., Barak, V. & Manny, J. Clinical applicability of intraperitoneal administration of nutrients and drugs. Harefuah 120, 76–80 (1991).

202.        Mandelbaum-Shavit, F., Barak, V., Saheb-Tamimi, K. & Grossowicz, N. Susceptibility of Legionella pneumophila grown extracellularly and in human monocytes to indole-3-propionic acid. Antimicrob. Agents Chemother. 35, 2526–2530 (1991).

203.        Gez, E., Strauss, N., Catane, R., Roisman, I. & Barak, V. The correlation between tumor response, serum prostatic-specific antigen and prostatic acid phosphatase in prostatic carcinoma patients receiving hormonetherapy. J. Tumor Marker Oncol. 6, 45–52 (1991).

204.        Roisman, I. et al. Fat necrosis below musculocutaneous flap mimicking carcinoma of breast. Ann. Plast. Surg. 26, 479–482 (1991).

205.        Meirow, D., Anteby, S. O., Ehrenfeld, M., Barak, V. & Pras, M. Serum CA-125 in familial mediterranean fever peritonitis. J. Tumor Marker Oncol. 6, 31–37 (1991).

206.        Ben‐Ishay, Z., Barak, V., Shoshan, S. & Prindull, G. Bone marrow stromal elements in murine leukemia: Decreased CSF‐producing fibroblasts and normal IL‐1 expression by macrophages. Eur. J. Haematol. 45, 203–208 (1990).

207.        Roizman, I., Gimon, Z. & Barak, V. Breast cancer and pregnancy. Harefuah 117, 441–445 (1989).

208.        Roisman, I., Gimon, Z. & Barak, V. Male breast cancer. Harefuah 117, 68–74 (1989).

209.        Ovadia, H. et al. Effect of interleukin-1 on adrenocortical activity in intact and hypothalamic deafferentated male rats. Exp. Brain Res. 76, 246–249 (1989).

210.        Roisman, I. et al. Solitary nonparasitic cyst of the liver: A rare cause of abdominal distension. Am. J. Gastroenterol. 84, 1095–1099 (1989).

211.        Barak, V., Carlin, D., Sulkes, A., Treves, A. & Biran, S. CA15-3 serum levels in breast cancer and other malignancies. Correlation with clinical course. Isr. J. Med. Sci. 24, 623–627 (1988).

212.        Polliack, A., Leizerowitz, R., Barak, V., Treves, A. J. & Gazitt, Y. Effects of retinoic acid and phorbol ester on lymphocytes and monocytes in B-lymphocytic leukemia. Isr. J. Med. Sci. 24, 522–532 (1988).

213.        Barak, V., Biran, S., Halimi, M. & Treves, A. J. The effect of estradiol on human myelomonocytic cells. II. Mechanism of enhancing activity of colony formation. J. Reprod. Immunol. 9, 355–363 (1986).

214.        Barak, V. et al. Detection of different interleukin-1 activities in human monocytes and monocytic cell lines. J. Biol. Response Mod. 5, 362–375 (1986).

215.        Barak, V. et al. Interleukin 1 inhibitory activity secreted by a human myelomonocytic cell line (M20). Eur. J. Immunol. 16, 1449–1452 (1986).

216.        Maoz, H. et al. Parameters affecting the in vitro maturation of human monocytes to macrophages. Int. J. Cell Cloning 4, 167–185 (1986).

217.        Treves, A. J. et al. In vitro differentiation and establishment of cell lines derived from human myelomonocytic leukemia cells. Immunol. Lett. 12, 225–230 (1986).

218.        Treves, A. J. et al. A new myelomonoblastic cell line (M20): Analysis of properties, differentiation, and comparison with other established lines of similar origin. Exp. Hematol. 13, 281–288 (1985).

219.        Maoz, H. et al. The effect of estradiol on human myelomonocytic cells. 1. Enhancement of colony formation. J. Reprod. Immunol. 7, 325–335 (1985).

220.        Treves, A. J. et al. Establishment of cell lines from somatic cell hybrids between human monocytes and mouse myeloma cells. J. Immunol. 132, 690–694 (1984).

221.        Barak, V., Fuks, Z., Galilli, N. & Treves, A. J. Selection and continuous growth of antigen‐specific human T cells by antigen‐treated monocytes. Eur. J. Immunol. 13, 952–956 (1983).

222.        Treves, A. J., Barak, V., Tal, T. & Fuks, Z. Constitutive secretion of interleukin 1 by human monocytes. Eur. J. Immunol. 13, 647–651 (1983).

223.        Treves, A. J., Tal, T., Barak, V. & Fuks, Z. Antigen presentation and regulatory functions of human monocytes in the in vitro response of lymphocytes against purified protein derivative of tuberculin (PPD). Eur. J. Immunol. 11, 487–492 (1981).

224.        Treves, A. J., Barak, V. & Fuks, Z. Characterization of human lymphocytes which proliferate “spontaneously” in vitro. Eur. J. Immunol. 10, 883–887 (1980).

225.        Treves, A. J., Barak, V. & Fuks, Z. In vitro proliferation of macrophage depleted human peripheral blood lymphocytes. Clin. Exp. Immunol. 38, 531–538 (1979).